Genentech, a member of the Roche Group, said the United States Food and Drug Administration has granted Priority Review to its supplemental Biologics License Application for Gazyva, or obinutuzumab, for adults with primary membranous nephropathy. The regulator is expected to decide on the proposed indication by November 2026.
The decision accelerates the review of an established biologic that is already approved for adults with active lupus nephritis receiving standard therapy and for specified haematological cancers. It does not amount to approval of Gazyva for primary membranous nephropathy, and it does not independently establish that the benefit-risk profile will satisfy the regulator.
If approved, however, Gazyva could become the first therapy specifically approved by the FDA for primary membranous nephropathy. Current immunosuppressive approaches are used without a disease-specific FDA label, creating a meaningful distinction between established clinical practice and formally authorised treatment.
The application is supported by the Phase III MAJESTY trial, in which Gazyva produced a substantially higher complete remission rate at two years than tacrolimus. The FDA had already granted Breakthrough Therapy designation to Gazyva for primary membranous nephropathy in April 2026, making Priority Review the second important regulatory signal for the programme within several months.
Why does Priority Review materially change the timetable without guaranteeing approval?
Priority Review is used when the FDA determines that an application may offer a significant improvement in treating, diagnosing or preventing a serious condition. It shortens the regulator’s review target, but it does not relax the evidentiary standard and should not be interpreted as a forecast of approval.
For Genentech, the designation converts the MAJESTY result from a positive clinical development into a time-defined regulatory catalyst. The November target means that questions surrounding the proposed indication, patient population, dosing schedule, safety monitoring and prescribing information should be resolved more quickly than under a standard review.
The application also benefits from Gazyva’s long regulatory and manufacturing history. The FDA is not evaluating an entirely new biological entity with no commercial experience. Regulators already have substantial information on obinutuzumab’s pharmacology, manufacturing controls, infusion requirements and safety profile from its use in haematological cancers and lupus nephritis.
That familiarity can reduce some development uncertainty, but indication-specific review remains important. Adults with primary membranous nephropathy may differ from oncology and lupus nephritis populations in baseline health, concomitant treatment, infection susceptibility and the duration over which benefit must be maintained. The FDA must therefore decide whether MAJESTY adequately supports the proposed kidney disease label rather than relying on experience from other indications.
What do the Phase III MAJESTY remission results show at the two year endpoint?
MAJESTY was a randomised, open-label, multicentre Phase III study involving 142 adults with primary membranous nephropathy. Participants were assigned equally to Gazyva or tacrolimus, with complete remission at week 104 serving as the primary endpoint.
At two years, 36.9% of adults assigned to Gazyva achieved complete remission, compared with 5.7% of those assigned to tacrolimus. The adjusted difference was 31.1 percentage points, with a 95% confidence interval of 18.2 to 44.0 and a p-value below 0.001.
Complete remission required a very low level of urinary protein, kidney function remaining within the protocol-defined range relative to baseline and the absence of specified intercurrent events such as treatment failure or escape therapy. This composite makes the outcome more rigorous than a reduction in proteinuria alone.
Key secondary results supported the primary finding. At week 104, complete or partial remission was achieved by approximately 51% of participants in the Gazyva group and 13% in the tacrolimus group. Complete remission also favoured Gazyva at the earlier week 76 assessment.
The evidence is more mature than topline data alone. The results were presented as a late-breaking oral presentation at the European Renal Association Congress in June 2026 and published in the New England Journal of Medicine. Publication provides clinicians and regulators with greater access to the trial methodology, endpoint definitions, safety findings and limitations.
Complete remission is clinically relevant because persistent proteinuria is associated with progressive kidney damage and an increased risk of kidney failure. Nevertheless, MAJESTY was not designed to establish a direct reduction in dialysis, transplantation or mortality. A later-ranked kidney function endpoint did not separate the treatment groups, and the trial’s hierarchical statistical testing stopped at that point.
The result therefore supports Gazyva’s ability to induce remission more effectively than the trial comparator over two years. Whether this translates into a measurable long-term reduction in kidney failure will require extended follow-up and real-world evidence.
Why does the tacrolimus comparator strengthen the result while limiting broader claims?
Tacrolimus is a calcineurin inhibitor used as an immunosuppressive treatment in membranous nephropathy. It can reduce proteinuria relatively quickly, but relapse after withdrawal is a recognised limitation because its effect may not persist once treatment is tapered.
In MAJESTY, participants in the comparator group received a year-long tacrolimus course followed by tapering. The week 104 endpoint therefore tested not only whether patients initially responded, but whether remission remained after tacrolimus withdrawal. Gazyva’s mechanism, which targets CD20-positive B cells involved in autoimmune activity, is intended to produce a more sustained immunological effect.
The comparator makes the trial clinically useful, but it does not establish Gazyva’s superiority over every treatment currently used for primary membranous nephropathy. The study did not directly compare Gazyva with rituximab, cyclophosphamide-based treatment or other risk-adapted regimens used by nephrologists.
Cross-trial comparisons would be especially unreliable because membranous nephropathy studies differ in baseline proteinuria, kidney function, antibody status, previous treatment, remission definitions and follow-up. The MAJESTY result supports superiority over the specific tacrolimus regimen studied, not a universal ranking of all available immunosuppressive strategies.
The open-label design is another consideration. Clinicians and participants knew which treatment had been assigned, although the primary outcome relied heavily on laboratory measurements and protocol-defined criteria. Awareness of treatment could still affect decisions around treatment discontinuation, escape therapy and the management of adverse events.
MAJESTY also enrolled a selected trial population with substantial proteinuria and generally preserved kidney function. Additional evidence will be needed to define how Gazyva performs in patients with advanced kidney impairment, lower-risk disease, different antigen profiles or previous resistance to B cell-directed therapy.
How should clinicians interpret the safety profile of prolonged B cell depletion?
Genentech reported that no new safety signal was identified in MAJESTY. Serious adverse events occurred in approximately 17% of participants assigned to Gazyva and 14% assigned to tacrolimus, while serious infections were reported in about 6% of each group.
Overall infection rates were also broadly similar, at approximately 61% with Gazyva and 57% with tacrolimus. Infusion-related reactions occurred in around 38% of Gazyva recipients, reflecting an important operational consideration even when reactions can be managed through premedication, monitoring, symptomatic treatment and changes to the infusion rate.
One patient from each randomised group died during escape therapy. The reported causes were COVID-19 pneumonia and cardiac arrest. These events do not independently establish that Gazyva caused either death, but they remain relevant to the complete safety assessment, particularly because some participants initially assigned to tacrolimus later received escape treatment.
Gazyva’s existing United States prescribing information includes boxed warnings concerning hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. It also describes risks including serious infections, infusion reactions, neutropenia, thrombocytopenia and hypersensitivity reactions.
A primary membranous nephropathy label would therefore require more than prescribing the biologic and scheduling an infusion. Providers would need appropriate screening, vaccination review, premedication, laboratory monitoring and the ability to manage serious infusion reactions. Long-lasting B cell depletion also makes infection surveillance relevant beyond the day of administration.
The trial’s comparative safety findings are reassuring within the disclosed follow-up, but they do not mean the treatment is free of risk. Longer observation will be particularly important because the therapeutic objective is durable immune control in a chronic condition rather than short-term symptom suppression.
What could FDA approval change for nephrology practices, payers and infusion centres?
An FDA-approved treatment would give nephrologists a disease-specific option supported by a positive global Phase III trial. It could also provide a clearer regulatory framework for treatment selection, monitoring and payer discussions than therapies used without a primary membranous nephropathy indication.
Adoption would still depend on how the final label defines eligible patients. The FDA could specify clinical characteristics, previous treatment requirements, dosing, monitoring or other conditions that influence the practical addressable population. The trial regimen used four 1,000 mg intravenous infusions during the first six months, but the approved schedule will depend on the regulator’s final decision.
Infusion capacity will be another practical factor. Gazyva requires administration by healthcare professionals with the facilities and medical support needed to manage potentially serious reactions. Nephrology practices without established infusion infrastructure may need to coordinate with hospitals, specialist centres or external infusion providers.
Payers are likely to compare the cost and durability of Gazyva with established off-label immunosuppressive approaches. A disease-specific approval would strengthen Genentech’s reimbursement case, but it would not automatically guarantee unrestricted coverage. Prior authorisation, clinical eligibility criteria and documentation of disease severity could shape access.
The economic argument will partly depend on whether durable remission reduces relapses, additional immunosuppression, hospital care and eventual kidney replacement therapy. MAJESTY provides a strong remission signal, but longer-term health-economic evidence will be required before reductions in dialysis or transplantation costs can be treated as demonstrated outcomes.
How does the filing expand Roche’s Gazyva strategy beyond oncology and lupus nephritis?
Gazyva began as a haematology medicine but has increasingly become an important component of Roche’s immunology and kidney disease strategy. It is already approved in the United States and European Union for adults with active lupus nephritis receiving standard therapy, while additional programmes are evaluating its use across systemic lupus erythematosus, idiopathic nephrotic syndrome and paediatric lupus nephritis.
MAJESTY is the fourth positive Phase III study of Gazyva in immune-mediated disease, following REGENCY in lupus nephritis, ALLEGORY in systemic lupus erythematosus and INShore in idiopathic nephrotic syndrome. The accumulation of positive studies provides Roche with a broader development platform centred on deeper B cell depletion rather than a single isolated label-expansion opportunity.
The FDA has also granted Priority Review to Gazyva in idiopathic nephrotic syndrome, while its systemic lupus erythematosus application is awaiting a separate regulatory decision. Success across several indications could establish shared medical, commercial and infusion infrastructure and improve Roche’s ability to reach nephrologists and immunology specialists.
Gazyva is part of a collaboration between Genentech and Biogen in the United States. Any primary membranous nephropathy approval would therefore extend an existing commercial asset rather than require construction of a new product platform from scratch.
The strategic value lies in lifecycle expansion and portfolio reinforcement. Primary membranous nephropathy is unlikely to determine Roche’s valuation on its own, but it could add a differentiated kidney disease indication and strengthen the company’s position in B cell-directed immunology.
What does Roche’s share performance say about investor expectations for this catalyst?
Roche Holding AG’s United States-traded ADRs closed at US$50.16 on July 14, down approximately 0.7% for the session. The price was roughly 3.9% lower across the preceding five trading sessions and about 1.7% lower than one month earlier, although it remained approximately 23.9% higher over 12 months.
The ADR’s 52-week range stood at US$37.51 to US$60.85. Because the Genentech announcement was released before the July 15 United States trading session, the July 14 close does not provide a clean measure of investor reaction to the Priority Review decision.
For a pharmaceutical group of Roche’s size, the Gazyva filing is better understood as a regulatory de-risking event than a stand-alone valuation driver. Investors must also assess Roche’s wider oncology, neurology, ophthalmology, diagnostics and immunology portfolios, along with upcoming financial results and multiple regulatory catalysts.
A November approval would strengthen sentiment around Roche’s expanding immunology strategy. A restrictive label, regulatory delay or rejection would have the opposite effect for the programme, although the impact on the broader group would probably remain proportionate to the relatively focused patient population.
Which clinical and commercial milestones will matter after the November FDA decision?
The immediate milestone is the FDA’s expected decision by November 2026. An approval would shift attention to the precise label, dosing schedule, safety monitoring requirements, launch timing, payer coverage and availability through infusion networks.
The European regulatory pathway also matters. MAJESTY data are being submitted to other health authorities, including the European Medicines Agency, creating the potential for a broader international label expansion if the evidence package receives favourable reviews.
Beyond regulation, longer-term follow-up must determine whether the remission advantage remains durable and whether it translates into sustained preservation of kidney function. Evidence involving advanced disease, previous B cell therapy, different antibody profiles and real-world treatment pathways would further define Gazyva’s clinical position.
The Priority Review removes uncertainty about the review timetable, but the decisive commercial test begins only if the FDA approves the indication. Genentech must then convert a strong two year remission result into accessible treatment, durable kidney outcomes and a convincing value proposition against lower-cost therapies already familiar to nephrologists.
